AZD-5863 is under clinical development by AstraZeneca and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AZD-5863’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AZD-5863 is under development for the treatment of CLDN18.2 positive advanced solid tumors including gastric cancer, adenocarcinoma of the gastroesophageal junction, pancreatic ductal adenocarcinoma, esophageal adenocarcinoma. The therapeutic candidate is a bi-specific monoclonal antibody which acts by targeting CD3 and tumor cell surface antigen claudin 18.2. It is being developed based on HBICE (HCAb-based immune cell connection Device platform) platfrom technology. It is administered through intravenous and subcutaneous route.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of AZD-5863’s drug-specific PTSR and LoA scores, buy the report here.